ApoGen Biotechnologies Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Out of Business

ApoGen Biotechnologies General Information

Description

Developer of advanced therapies intended to break drug resistance in cancer. The company develops therapies that target key drivers of ongoing deoxyribonucleic acid mutation and tumor evolution, thereby enabling physicians to slow or stop cancer genome mutation.

Contact Information

Website
www.apogenbiotech.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 2815 Eastlake Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 2815 Eastlake Avenue East
  • Suite 300
  • Seattle, WA 98102
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ApoGen Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 25-May-2021 0000 Completed Out of Business
4. Secondary Transaction - Private 0000 Completed Generating Revenue
3. Early Stage VC (Series A) 23-Aug-2018 0000 0000 000.00 Completed Generating Revenue
2. Seed Round Completed Startup
1. Spin-Off 01-Jan-2014 Completed Startup
To view ApoGen Biotechnologies’s complete valuation and funding history, request access »

ApoGen Biotechnologies Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00 00.000
To view ApoGen Biotechnologies’s complete cap table history, request access »

ApoGen Biotechnologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of advanced therapies intended to break drug resistance in cancer. The company develops therapies that target
Drug Discovery
Seattle, WA
10 As of 2021
0000
00000000 00 0000

0000 0

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000000000000
Santa Monica, CA
0000 As of 0000
00000
000.00 0000-00-00
000000&0 00000

000000

iscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ApoGen Biotechnologies Competitors (71)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
Senti Bio Formerly VC-backed South San Francisco, CA 00 00000 000000000000 00000
Cogent Biosciences Formerly VC-backed Waltham, MA 000 00000 000000000 00000
You’re viewing 5 of 71 competitors. Get the full list »

ApoGen Biotechnologies Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

ApoGen Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-3004695-A Nucleic acid filters Inactive 08-Jul-1994 000000000

ApoGen Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

ApoGen Biotechnologies FAQs

  • When was ApoGen Biotechnologies founded?

    ApoGen Biotechnologies was founded in 2014.

  • Who is the founder of ApoGen Biotechnologies?

    Daniel Harki Ph.D, Reuben Harris Ph.D, and John Santini Ph.D are the founders of ApoGen Biotechnologies.

  • Where is ApoGen Biotechnologies headquartered?

    ApoGen Biotechnologies is headquartered in Seattle, WA.

  • What is the size of ApoGen Biotechnologies?

    ApoGen Biotechnologies has 10 total employees.

  • What industry is ApoGen Biotechnologies in?

    ApoGen Biotechnologies’s primary industry is Drug Discovery.

  • Is ApoGen Biotechnologies a private or public company?

    ApoGen Biotechnologies is a Private company.

  • What is ApoGen Biotechnologies’s current revenue?

    The current revenue for ApoGen Biotechnologies is 000000.

  • How much funding has ApoGen Biotechnologies raised over time?

    ApoGen Biotechnologies has raised $11M.

  • Who are ApoGen Biotechnologies’s competitors?

    Kite Pharma, NexImmune, Iovance Biotherapeutics, Senti Bio, and Cogent Biosciences are some of the 71 competitors of ApoGen Biotechnologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »